Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity
Environmental and Molecular Mutagenesis · 2019-04 · 60 (3) · 302-304
DOI: 10.1002/em.22260 ↗Kurz gefasst
Leserbrief in der Zeitschrift Environmental and Molecular Mutagenesis, online erschienen am 07.12.2018. Verfasst von Pedro Aurio Maia Filho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Federal University of Ceará, Fortaleza, Brazil. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Sickle cell anemia (SCA) is a hereditary hematological disease that is characterized by a point mutation in the beta globin S gene and has no specific treatment; hydroxyurea (HU) is the only therapeutic agent used in clinical practice. In the present study, we evaluated the deoxyribonucleic acid (DNA) damage index (DI) and chromosomal damage in leukocytes of adult patients with SCA with and without HU. The DI was assessed by the comet assay and chromosomal damage by the leukocyte micronucleus test of adult patients treated with HU (SCA‐HU) and without the use of HU (SCA‐NoHU). This is a cross‐sectional study with 77 patients with SCA who attended a referral hospital in Fortaleza, Brazil. The control group (CG) consisted of 58 reportedly healthy individuals. The comparisons of means were performed by analysis of variance and Tukey's post‐test. Values of P < 0.05 were considered statistically significant. SCA‐NoHU patients had statistically higher DI values and a statistically significantly higher frequency of micronuclei compared to the CG. In addition, HU treatment accentuated DNA lesions by significantly increasing both parameters in treated patients (SCA‐HU). HU potentiates DNA damage and the occurrence of chromosomal damage, which may promote genomic instability, mutation occurrence, and carcinogenesis. Studies are needed to evaluate the involved pathways, repair mechanisms, and the clinical impact that such damage can cause. Environ. Mol. Mutagen. 60:302–304, 2019. © 2018 Wiley Periodicals, Inc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Federal University of Ceará, Fortaleza, Brazil.
- Nucleus of Research and Development of Medicines, Federal University of Ceará, Fortaleza, Brazil.
ORCID-Profile: Pedro Aurio Maia Filho
Zitieren
APA
Maia Filho, P. A., Pereira, J. F., Almeida Filho, T. P., Cavalcanti, B. C., Sousa, J. C., & Lemes, R. P. G. (2019). Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity. Environmental and Molecular Mutagenesis, 60(3), 302-304. https://doi.org/10.1002/em.22260
Vancouver
Maia Filho PA, Pereira JF, Almeida Filho TP, Cavalcanti BC, Sousa JC, Lemes RPG. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity. Environmental and Molecular Mutagenesis. 2019;60(3):302-304. doi:10.1002/em.22260
BibTeX
@article{MaiaFilho2019,
author = {Maia Filho, Pedro Aurio and Pereira, Jamilly Florêncio and Almeida Filho, Tarcísio Paulo de and Cavalcanti, Bruno Coêlho and Sousa, Juliana Cordeiro de and Lemes, Romélia Pinheiro Gonçalves},
title = {Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity},
journal = {Environmental and Molecular Mutagenesis},
year = {2019},
volume = {60},
number = {3},
pages = {302--304},
doi = {10.1002/em.22260}
}
EUVIMED